Omega Healthcare Invts 주식 (NYSE: OHI)

Omega Healthcare Invts (NYSE:OHI) 주식

Omega Healthcare Invts

Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).

Omega Healthcare Investors, Inc. Common Stock

Omega Healthcare Investors Inc

OHIO ART CO by Ohio Art Company (The)

Ohio Valley Banc Corporation

News

Reported Earlier, Omega Healthcare Prices $600M Public Offering Of 5.200% Senior Notes Due 2030; Proceeds Target Debt Repayment

Ratings for Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Omega Healthcare Invts and provided 12-month price targets. The average target is $39.25, accompanied by a high estimate of $41.00 and a low estimate of $38.00. This current average has decreased by 2.48% from the previous average price target of $40.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1748894447_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Omega Healthcare Invts among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omega Healthcare Invts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Omega Healthcare Invts compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Omega Healthcare Invts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Omega Healthcare Invts's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OHI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Omega Healthcare Invts analyst ratings.</a>
<h2>Delving into Omega Healthcare Invts's Background</h2>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Financial Milestones: Omega Healthcare Invts's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Omega Healthcare Invts showcased positive performance, achieving a revenue growth rate of 13.76% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 39.39%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Omega Healthcare Invts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.35%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Omega Healthcare Invts's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.11%, the company showcases efficient use of assets and strong financial health.
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.94.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Omega Healthcare Invts

Wells Fargo analyst Connor Siversky maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Equal-Weight and lowers the price target from $39 to $38.

Price Target

Wells Fargo Maintains Equal-Weight on Omega Healthcare Invts, Lowers Price Target to $38

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) is a company that is &#8220;incredibly well-run that has tremendous growth.&#8221; He recommended buying the stock &#8220;given the fact that so many of these other stocks actually even have higher <a href="https://www.benzinga.com/quote/ALAB/earnings">price-to-earnings multiples.&#8221;</a>
Morgan Stanley analyst Joseph Moore supported his view by upgrading the rating for Astera Labs from Equal-Weight to Overweight and maintaining the price target of $99.
When asked about Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), he said, &#8220;I think you're right to be worried.&#8221;
On the earnings front, Omega Healthcare Investors reported quarterly earnings of 75 cents per share on May 1, beating the analyst consensus estimate of 74 cents per share. The company reported quarterly sales of $276.80 million, missing the analyst consensus estimate of $288.69 million.
Price Action:
<ul class="wp-block-list">
<li>Omega Healthcare Investors shares fell 1.4% to settle at $35.91 on Wednesday.</li>
<li>Astera Labs shares rose 3.3% to close at $90.66 during the session.</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a></li>
</ul>
Photo: Shutterstock

Media

Trading Ideas

ALAB

Jim Cramer: Astera Labs Has 'Tremendous Growth'

New partnership offers Omega's operator partners exclusive benefits; Omega takes equity stake in Sunbound.
WASHINGTON, May 13, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426049-1&amp;h=738334504&amp;u=https%3A%2F%2Fwww.sunboundhomes.com%2F&amp;a=Sunbound">Sunbound</a>, a leader in finance and accounts receivable solutions for senior living operators, today announced a strategic partnership with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426049-1&amp;h=737281245&amp;u=https%3A%2F%2Fwww.omegahealthcare.com%2F&amp;a=Omega+Healthcare+Investors">Omega Healthcare Investors</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), one of the nation's premier real estate investment trusts (REITs) that provides financing and capital solutions to Skilled Nursing Facility (SNF) and Assisted Living Facility (ALF) operators across the U.S. and the U.K. Through this agreement, Omega's extensive network of operator partners will receive preferred access and pricing to Sunbound's industry-leading payments, accounts receivable and financing solutions.

Sunbound Announces Strategic Partnership with Omega Healthcare Investors To Enhance Financing Solutions

WIIM

Omega Healthcare Investors shares are trading lower after the company reported a Q1 revenue miss.

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) raises FY2025 FFO guidance from $2.90-$2.98 to $2.95-$3.01 vs $2.97 analyst estimate..

Guidance

Omega Healthcare Invts Raises FY2025 FFO Guidance from $2.90-$2.98 to $2.95-$3.01 vs $2.97 Est

Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.74 by 1.35 percent. This is a 10.29 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $276.80 million which missed the analyst consensus estimate of $288.69 million by 4.12 percent. This is a 13.77 percent increase over sales of $243.30 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Omega Healthcare Invts Q1 FFO $0.75 Beats $0.74 Estimate, Sales $276.80M Miss $288.69M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

President Donald Trump&#8216;s ongoing tariff policy changes have resulted in persistent market volatility and uncertainty. This has increased investors' appetite for stable, defensive stocks paying steady dividends. Dividend stocks have <a href="https://www.hartfordfunds.com/dam/en/docs/pub/whitepapers/WP106.pdf">contributed</a> significantly to overall market returns during the 1940s, 1960s, and 1970s, when average annual total returns were lower.
About seven months ago, a dividend investor <a href="https://www.reddit.com/r/dividends/comments/1fldncg/finally_hit_300k_goal/">shared</a> his monthly dividend income details and portfolio on r/Dividends — a Reddit discussion board with over 700,000 followers. The income report shared by the investor showed his monthly dividend income was $23,800, with a projected annual dividend income of just over $300,000.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
The investor, in his mid-50s, said he had about 150 holdings in his portfolio worth roughly $4.4 million. Asked how he was able to accumulate wealth to build such a large portfolio, he said it took him years to reach this milestone:
"Started at $3.50 per hour. Went back to school in my early 30s as did my wife. Definitely no inheritance and student loans to boot. Just 35 years of investing."
The investor said over $2 million of his wealth came from "decades of trading" biotech company Immunomedics, which was <a href="https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics">bought</a> by Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) in 2020 for $88 per share.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Let's take a look at some of the biggest holdings of the investor.
BlackRock Science and Technolgy Term Trust
BlackRock Science and Technology Term Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSTZ#NYSE">BSTZ</a>) was the biggest holding of the investor. The closed-end equity fund invests in science and technology companies and also generates income by selling call options on stocks in its portfolio. It has a dividend yield of about 9%.&nbsp;
Nuveen Real Asset Income and Growth Fund
The Nuveen Real Asset Income and Growth Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JRI#NYSE">JRI</a>) invests in companies related to infrastructure projects, facilities, and services, as well as REITs. Among the top holdings of the fund are Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>), Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>), Gaming and Leisure Properties (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>), Simon Property (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) and Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>).
DoubleLine Income Solutions Fund
DoubleLine Income Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSL#NYSE">DSL</a>) is a closed-end fund focusing on income-generating fixed-income securities. It yields about 12% and pays monthly.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Kayne Anderson Energy Infrastructure Fund&nbsp;
The Kayne Anderson Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KYN#NYSE">KYN</a>) invests in midstream, natural gas &amp; LNG infrastructure, and power infrastructure companies. The fund has a dividend yield of over 8%.
Western Asset High Income Opportunity Fund
Another closed-end fund in the portfolio, Western Asset High Income Opportunity Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIO#NYSE">HIO</a>) primarily invests in high-yield corporate debt securities and preferred stocks for income generation and capital appreciation. The fund has a distribution rate of over 10%.&nbsp;
Voya Infrastructure, Industrials and Materials Fund
The Voya Infrastructure, Industrials and Materials Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDE#NYSE">IDE</a>) invests in companies in the infrastructure, industrials and materials sectors. Cisco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), Uber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) are among the fund's biggest holdings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

BSTZ

CSCO

GILD

GLPI

TMUS

UBER

Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour  —  'Just 35 Years of Investing'

Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) is a real estate investment trust providing financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities located in the U.S. and the U.K.
It is set to report its Q1 2025 earnings on May 1. Wall Street analysts expect the company to post EPS of $0.75, up from $0.68 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $276.66 million, up from $243.30 million a year earlier.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></li>
</ul>
<h2 class="wp-block-heading">If You Bought Omega Healthcare Stock 10 Years Ago</h2>
The company's stock traded at approximately $40.41 per share 10 years ago. If you had invested $10,000, you could have bought roughly 247 shares. Currently, shares trade at $38, meaning your investment's value could have declined to $9,404 from stock price depreciation. However, Omega Healthcare also paid dividends during these 10 years.&nbsp;
Omega Healthcare's dividend yield is currently 7.05%. Over the last 10 years, it has paid about $24.11 in dividends per share, which means you could have made $5,966 from dividends alone.&nbsp;
Summing up $9,404 and $5,966, we end up with the final value of your investment, which is $15,370. This is how much you could have made if you had invested $10,000 in Omega Healthcare stock 10 years ago. This means a total return of 53.7%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 235%.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
Omega Healthcare has a consensus rating of "Buy" and a price target of $36.11 based on the ratings of 21 analysts. The price target implies a nearly 5% potential downside from the current stock price.
On Feb. 5, the company announced its Q4 2024 earnings, posting FFO of $0.74, compared to the consensus estimate of $0.73, and revenues of $279.318 million, compared to the consensus of $275.668 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43510274/omega-healthcare-invts-q4-2024-ffo-0-74-beats-0-73-estimate-sales-279-318m-beat-275-668m-estimate">Benzinga</a>.
"The backdrop continues to be favorable. Operating metrics remain strong, with both occupancy and coverage modestly improving in the quarter. The pipeline remains very active, and we have a cost of capital that should allow us to continue to accretively invest," CEO Taylor Pickett said.
See Also: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a>
The company provided its full-year 2025 guidance, expecting adjusted FFO to be between $2.90 and $2.98 per diluted share.
Given the expected downside potential, growth-focused investors may not find Omega Healthcare stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 7.05%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/03/44450148/why-pepsico-restaurant-brands-and-fifth-third-bancorp-are-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

If You Invested $10K In Omega Healthcare Stock 10 Years Ago, How Much Would You Have Now?

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.40%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and slashed the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest HR news</a>.</li>
</ul>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.15%</li>
<li>Wells Fargo analyst Connor Siversky downgraded the stock from Overweight to Equal-Weight and lowered the price target from $41 to $39 on March 27, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and increased the price target from $38 to $39 on March 18, 2025. This analyst has an accuracy rate of 70%</li>
<li>Recent News: On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">OHI news</a></li>
</ul>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 7.32%</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and increased the price target from $17.51 to $18.54 on Dec. 18, 2024. This analyst has an accuracy rate of 75%.</li>
<li>TD Cowen analyst Lance Vitanza initiated coverage on the stock with a Hold rating and a price target of $16.48 on July 16, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Feb. 25, Outfront Media reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0328">latest OUT news</a> </li>
</ul>
<figure class="wp-block-embed"> 
<div class="wp-block-embed__wrapper">
<a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock" title="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock</a>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Dividends

Pre-Market Outlook

Markets

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 7% Dividend Yields

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Blayne Curtis downgraded the rating for Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Hold and lowered the price target from $135 to $120. Advanced Micro Devices shares closed at $110.19 on Wednesday. <a href="https://www.benzinga.com/quote/amd/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ryan Brinkman downgraded OPENLANE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAR#NYSE">KAR</a>) from Overweight to Neutral and lowered the price target from $23 to $20. Openlane shares closed at $20.99 on Wednesday. <a href="https://www.benzinga.com/quote/KAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Rajat Gupta downgraded the rating for TrueCar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) from Neutral to Underweight. TrueCar shares closed at $1.79 on Wednesday. <a href="https://www.benzinga.com/quote/TRUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Rajat Gupta downgraded CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) from Overweight to Neutral and cut the price target from $42 to $34. CarGurus shares closed at $31.33 on Wednesday. <a href="https://www.benzinga.com/quote/CARG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Connor Siversky downgraded Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Overweight to Equal-Weight and lowered the price target from $41 to $39. Omega Healthcare shares closed at $37.72 on Wednesday.  <a href="https://www.benzinga.com/quote/OHI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44496478/top-2-industrials-stocks-that-may-crash-in-q1">Top 2 Industrials Stocks That May Crash In Q1</a></li>
</ul>

Downgrades

CARG

TRUE

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wells Fargo analyst Connor Siversky downgrades Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Overweight to Equal-Weight and lowers the price target from $41 to $39.

Wells Fargo Downgrades Omega Healthcare Invts to Equal-Weight, Lowers Price Target to $39

Truist Securities analyst Michael Lewis maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $38 to $39.

Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $39

LAMR

Shares of real estate ETFs are trading lower following a rise in treasury yields, which can raise borrowing costs for firms and enhance the relative attractiveness of bonds for income-oriented investors.

Wells Fargo analyst John Kilichowski maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Overweight and lowers the price target from $43 to $41.

Wells Fargo Maintains Overweight on Omega Healthcare Invts, Lowers Price Target to $41

CBRE

EQIX

WELL

WHLR

Shares of REIT and utility stocks are trading lower amid overall market weakness. Rising Treasury yields may be driving a rotation out of income-paying sectors.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.33%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and increased the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">HR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="397" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png" alt="" class="wp-image-798244" style="width:517px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-300x133.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142718/image-208-768x340.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.27%</li>
<li>JMP Securities analyst Aaron Hecht reiterated a Market Perform rating on Feb. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Feb. 5, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png" alt="" class="wp-image-798252" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25143021/image-211-768x682.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 6.75%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and increased the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Jan. 27, EPR Properties elected John Peter (JP) Suarez to its Board of Trustees.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1">latest EPR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="807" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png" alt="" class="wp-image-798248" style="width:506px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25142824/image-210-768x683.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43937701/how-to-earn-500-a-month-from-lowes-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Lowe&#8217;s Stock Ahead Of Q4 Earnings</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 6% Dividend Yields

JMP Securities analyst Aaron Hecht reiterates Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Omega Healthcare Invtsto Market Perform

Press Releases

Real Estate

All 15 Maplewood Senior Living Communities and Inspῑr Carnegie Hill Receive Reputation.com's Esteemed Awards

Ortelius Nominates Six Highly Qualified and Independent Candidates for Election to the Board of Brookdale Senior Living Inc.

Management

Plymouth Industrial REIT Appoints Robert O. Stephenson to Board of Directors

Omega Announces First Quarter Earnings Release Date and Conference Call

Omega Announces Quarterly Dividend

Omega Reports First Quarter 2025 Results and Recent Developments

Omega Issues Business Update

Contracts

Sunbound Announces Strategic Partnership with Omega Healthcare Investors

Omega Announces Pricing of Its $600,000,000 Senior Notes Offering

AVIV

GMRE

NTST

PLYM

RYAM

American Healthcare REIT, Inc. Common Stock

American Healthcare REIT

Alexandria Real Estate Equities, Inc. Common Stock

Alexandria Real Estate

Community Healthcare Trust Incorporated Common Stock

Community Healthcare

CareTrust REIT

Diversified Healthcare Trust - Common Shares of Beneficial Interest

Diversified Healthcare

Healthpeak Properties

Global Medical REIT

Healthcare Realty Trust Incorporated Common Stock

Healthcare Realty Trust

LTC Properties

Medical Properties Trust, Inc. common stock

Medical Properties Trust

National Health Investors, Inc. Common Stock

National Health Investors

Sabra Health Care REIT, Inc. - Common Stock

Sabra Health Care REIT

Sila Realty Trust

Strawberry Fields REIT, Inc. Common Stock

Strawberry Fields REIT

Universal Health Realty Income Trust Common Stock

Universal Health Realty

Ventas

Welltower

Wells Fargo

Truist Securities

BMO Capital

Mizuho

Comments

Omega Healthcare Invts

뉴스

파트너 / 기고자

벤징가 글로벌